Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Viral and Host Factors in the Transmission and Pathogenesis of HIV

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Rockefeller University
Sponsor:
Information provided by (Responsible Party):
Rockefeller University
ClinicalTrials.gov Identifier:
NCT00219947
First received: September 20, 2005
Last updated: November 4, 2014
Last verified: November 2014

September 20, 2005
November 4, 2014
July 2000
July 2016   (final data collection date for primary outcome measure)
Participants are tested for HIV-1 RNA levels, the presence of antibodies to HIV antigens, and T cell subsets [ Time Frame: first visit ] [ Designated as safety issue: No ]
Participants are tested for HIV-1 RNA levels, the presence of antibodies to HIV antigens, and T cell subsets
Complete list of historical versions of study NCT00219947 on ClinicalTrials.gov Archive Site
Data will be used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment [ Time Frame: first visit ] [ Designated as safety issue: No ]
Data will be used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment
Not Provided
Not Provided
 
Viral and Host Factors in the Transmission and Pathogenesis of HIV
Viral and Host Factors in the Transmission and Pathogenesis of HIV

To study the collection of blood from individuals known to be at high risk for HIV-infection or who have been recently infected with HIV.

The data collected are used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment Guidelines.

This phlebotomy protocol permits the collection of blood from individuals known to be at high risk for HIV-infection or who have been recently infected with HIV.

Participants will have from 10 to 60 ml (approximately 1 to 4 tablespoons) of blood drawn for one or all of the following tests:

  • T cell subset enumeration
  • Serologic reactivity with HIV antigens
  • Viral load assays by bDNA, PCR, or RT-PCR
  • Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
  • HIV-1 Resistance Testing

These data are used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment Guidelines

Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

whole blood

Non-Probability Sample

Subjects are either referred by primary health care providers, self-referred, or may be seeking enrollment in other ADARC clinical trials in the NYC area.

HIV Infections
Other: blood draw
  • T cell subset enumeration
  • Serologic reactivity with HIV antigens
  • Viral load assays by bDNA, PCR, or RT-PCR
  • Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
  • HIV-1 Resistance Testing
  • high risk
    Blood draw from individuals known to be or at high risk for HIV-infection
    Intervention: Other: blood draw
  • diagnosed
    Blood draw f rom individuals diagnosed with HIV infection
    Intervention: Other: blood draw
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
July 2016
July 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

recently infected with HIV-1 HIV-1 negative, and at high risk for infection

Exclusion Criteria:

none

Both
16 Years and older
No
Contact: Melissa La Mar 212-327-7280 mlamar@rockefeller.edu
United States
 
NCT00219947
MMA-448
No
Rockefeller University
Rockefeller University
Not Provided
Principal Investigator: Martin M Markowitz, MD Rockefeller University
Rockefeller University
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP